不活化ワクチンの世界市場

不活化ワクチンの世界市場は2030年までに541億米ドルに達する見込み

2024年に416億米ドルと推定される不活化ワクチンの世界市場は、2024～2030年の分析期間においてCAGR 4.5%で成長し、2030年には541億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるウイルスワクチンは、CAGR 5.3%を記録し、分析期間終了時には353億米ドルに達すると予測されます。細菌ワクチン分野の成長率は、分析期間中CAGR 3.0%と推定されます。

米国市場は113億米ドルと推定、中国はCAGR 8.3％で成長予測

米国の不活化ワクチン市場は、2024年に113億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに113億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.8%と3.5%と予測されています。欧州では、ドイツがCAGR 2.6%で成長すると予測されています。

世界の不活化ワクチン市場- 主要動向と促進要因のまとめ

急速に進化する予防接種市場において、不活化ワクチンはどのように関連性を維持しているのか？

化学的または物理的処理によって死滅させた病原体を含む不活化ワクチンは、その強固な安全性プロファイルと幅広い適用性により、世界の予防接種活動の要としての役割を果たし続けています。生ワクチンとは異なり、不活化製剤は病原性が復活するリスクがないため、免疫不全者、高齢者、妊婦にとって特に重要です。これらのワクチンは、A型肝炎、狂犬病、ポリオ（IPV）、日本脳炎、インフルエンザなどの疾病に広く使用されており、パンデミックへの備えのシナリオにおいても新たな関連性が出てきています。

A型肝炎や狂犬病、ポリオ（IPV）、日本脳炎、インフルエンザなど、パンデミック（世界的大流行）に備えるための予防接種も行われています。政府および国際保健機関は、特にコールドチェーンの安定性、規制当局の承認、ワクチンの安全性に対する国民の信頼が最優先事項である地域において、調達戦略において不活化ワクチンを優先し続ける。さらに、不活化ワクチンの配合製剤、特に小児用予防接種スケジュールにおける役割は、世界市場においてその関連性を強めています。

どのような技術革新が不活化ワクチンの開発と提供を変えているのでしょうか？

技術革新の波は不活化ワクチンプラットフォームの拡張性、純度、免疫原性を向上させています。Vero細胞株やMDCK細胞株のような細胞培養ベースの製造法は、従来の卵ベースや動物由来の基質に取って代わりつつあり、より安全で一貫性のある製造をもたらしています。これらのプラットフォームは、ポリオ、インフルエンザ、狂犬病に対するワクチンの製造に特に有用です。さらに、アルミニウム塩、MF59、AS03のような新しいアジュバントが、免疫反応を増幅し、必要な投与回数を減らすために組み込まれています。

もう一つの重要な進歩は、耐熱性製剤や凍結乾燥製剤の開発であり、これらは高温環境や低資源環境でも効力を維持できるように設計されています。これは、コールドチェーン・ロジスティクスの維持が困難なアフリカや東南アジアの農村地域で特に重要です。さらに、適切な保管、トレーサビリティ、使用法の遵守を確実にするため、デジタル追跡システムやスマート包装技術が統合されつつあります。こうした改善により、ワクチンのロジスティクスが最適化されるだけでなく、特にパンデミックや突発的な疾病発生のような緊急事態の際に、世界の集団予防接種キャンペーンが支援されるようになっています。

不活化ワクチンの需要を促進している疾患ターゲットと地域は？

不活化ワクチンの需要は、小児予防接種プログラムやアジア太平洋、ラテンアメリカ、アフリカの一部の感染症対策において特に高まっています。また、不活化狂犬病ワクチンは、流行国における曝露後予防の管理に不可欠です。季節性インフルエンザワクチン接種は、不活化4価製剤に依存することが多く、北米と欧州では、特に高齢化社会と慢性疾患を抱える人々において、依然として主要な成長分野となっています。

COVID-19のような新たな感染症の脅威も、不活化ワクチン・プラットフォームに対する世界の関心を再燃させています。従来の不活化法を用いて開発されたいくつかのCOVID-19ワクチンは、中国、インド、アラブ首長国連邦などの国々で大規模に展開されており、危機対応におけるこのプラットフォームの迅速性と拡張性を示しています。さらに、鳥インフルエンザやダニ媒介性脳炎といった人獣共通感染症の脅威が、ヒト用と動物用の両方で不活化ワクチンの開発と展開をさらに後押ししています。官民パートナーシップにより、低所得国での現地製造が支援され、地理的・経済的格差を超えてこれらのワクチンへの公平なアクセスが確保されています。

不活化ワクチン市場の成長は、いくつかの要因によって牽引されています。

ワクチンの安全性、特に脆弱な集団や免疫不全患者への使用に対する世界の関心の高まりが、この市場の成長を牽引しています。細胞培養生産とアジュバント開発における技術的進歩は、不活化ワクチンの効率性、効力、拡張性を向上させ、定期的および緊急の予防接種キャンペーンに適しています。人獣共通感染症や新たなパンデミックの流行も、柔軟で迅速な対応可能なワクチンプラットフォームへの需要を加速させており、不活化ワクチンが重要であることが証明されています。

さらに、ポリオ常在国や移行国におけるOPVからIPVへの移行などの政策転換により、不活化製剤の採用基盤が拡大しています。狂犬病対策、A型肝炎予防、新型インフルエンザ対策などの政府支援プログラムは、Gavi、WHO、地域保健連合などの支援を受けて、市場の成長をさらに後押ししています。IPVやその他の不活化ワクチンを含む小児用混合ワクチンの普及が進み、予防接種スケジュールの合理化とコンプライアンスの向上が進んでいます。技術移転や国際的な資金援助に支えられた新興国地域でのワクチン製造インフラの拡充は、製造コストの削減と世界の供給安全性の向上に役立っており、不活化ワクチン市場の持続的成長をさらに後押ししています。

セグメント

ワクチンタイプ（ウイルスワクチンタイプ、細菌ワクチンタイプ）、不活化法（溶媒洗浄法、放射線法,、pH濃度、その他の不活化法）、投与経路（経口、皮下、静脈注射）、エンドユーザー（病院エンドユーザー、専門クリニックエンドユーザー、在宅医療エンドユーザー、その他のエンドユーザー）

調査対象企業の例（合計 36注目の企業）

• Astellas Pharma Inc.
• Bavarian Nordic A/S
• Bharat Biotech International Ltd.
• Biological E Limited
• Boehringer Ingelheim International GmbH
• CanSino Biologics Inc.
• CSL Limited
• Daiichi Sankyo Company, Limited
• Emergent BioSolutions Inc.
• GlaxoSmithKline plc
• Hualan Biological Engineering Inc.
• Inovio Pharmaceuticals, Inc.
• Johnson & Johnson Services Inc.
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Novavax, Inc.
• Pfizer Inc.
• Sanofi Pasteur
• Serum Institute of India Pvt. Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Inactivated Vaccines Market to Reach US$54.1 Billion by 2030

The global market for Inactivated Vaccines estimated at US$41.6 Billion in the year 2024, is expected to reach US$54.1 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Viral Vaccine, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$35.3 Billion by the end of the analysis period. Growth in the Bacterial Vaccine segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.3 Billion While China is Forecast to Grow at 8.3% CAGR

The Inactivated Vaccines market in the U.S. is estimated at US$11.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$11.3 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global Inactivated Vaccines Market - Key Trends & Drivers Summarized

How Do Inactivated Vaccines Maintain Their Relevance in a Rapidly Evolving Immunization Landscape?

Inactivated vaccines, which contain pathogens that have been killed through chemical or physical processes, continue to serve as a cornerstone of global immunization efforts due to their robust safety profile and broad applicability. Unlike live-attenuated vaccines, inactivated formulations pose no risk of reversion to virulence, making them especially critical for immunocompromised individuals, the elderly, and pregnant women. These vaccines are widely used for diseases such as hepatitis A, rabies, polio (IPV), Japanese encephalitis, and influenza, with emerging relevance in pandemic preparedness scenarios.

Their non-replicating nature means booster doses are often required, yet this trade-off is balanced by their ability to induce strong humoral immune responses with well-understood safety parameters. Governments and global health agencies continue to prioritize inactivated vaccines in their procurement strategies, particularly in regions where cold chain stability, regulatory acceptance, and public trust in vaccine safety are high priorities. Moreover, the role of inactivated vaccines in combination formulations-particularly in pediatric immunization schedules-is reinforcing their relevance across global markets.

What Technological Innovations Are Reshaping the Development and Delivery of Inactivated Vaccines?

A wave of innovation is enhancing the scalability, purity, and immunogenicity of inactivated vaccine platforms. Cell culture-based production methods, such as Vero and MDCK cell lines, are replacing traditional egg-based and animal-derived substrates, resulting in safer and more consistent manufacturing. These platforms are particularly useful for producing vaccines against polio, influenza, and rabies. Moreover, novel adjuvants like aluminum salts, MF59, and AS03 are being incorporated to amplify immune responses and reduce the number of required doses.

Another critical advancement is the development of thermostable and lyophilized formulations, which are designed to maintain potency in high-temperature or low-resource settings. This is especially important in rural regions of Africa and Southeast Asia where cold chain logistics are difficult to maintain. In addition, digital tracking systems and smart packaging technologies are being integrated to ensure proper storage, traceability, and usage compliance. These improvements are not only optimizing vaccine logistics but also supporting global mass immunization campaigns, particularly during emergencies like pandemics or sudden disease outbreaks.

Which Disease Targets and Geographies Are Fueling Demand for Inactivated Vaccines?

Demand for inactivated vaccines is particularly strong in pediatric immunization programs and in infectious disease control initiatives across Asia-Pacific, Latin America, and parts of Africa. IPV is increasingly replacing oral polio vaccines as countries move into the final stages of polio eradication, while inactivated rabies vaccines are crucial in managing post-exposure prophylaxis in endemic countries. Seasonal influenza vaccination, which often relies on inactivated quadrivalent formulations, remains a major growth segment in North America and Europe, especially in aging populations and those with chronic diseases.

Emerging infectious threats such as COVID-19 have also reignited global interest in inactivated vaccine platforms. Several COVID-19 vaccines developed using traditional inactivation methods have been deployed at scale in countries like China, India, and the UAE, showcasing the speed and scalability of this platform in crisis response. Additionally, zoonotic threats such as avian influenza and tick-borne encephalitis are further driving the development and deployment of inactivated vaccines for both human and veterinary applications. Public-private partnerships are supporting local manufacturing in lower-income nations, ensuring more equitable access to these vaccines across geographic and economic divides.

The Growth in the Inactivated Vaccines Market Is Driven by Several Factors…

It is driven by the increasing global focus on vaccine safety, particularly for use in vulnerable populations and immunocompromised individuals. Technological advancements in cell culture production and adjuvant development are improving the efficiency, potency, and scalability of inactivated vaccines, making them more suitable for both routine and emergency immunization campaigns. The rising prevalence of zoonotic diseases and emerging pandemics is also accelerating demand for flexible and rapid-response vaccine platforms, in which inactivated vaccines have proven critical.

Additionally, policy shifts such as the transition from OPV to IPV in polio-endemic and transitioning countries are expanding the adoption base of inactivated formulations. Government-supported programs in rabies control, hepatitis A prevention, and pandemic influenza preparedness are further bolstering market growth, supported by Gavi, WHO, and regional health alliances. Increasing uptake of combination pediatric vaccines, including IPV and other inactivated components, is streamlining immunization schedules and improving compliance. The expansion of vaccine manufacturing infrastructure in developing regions, supported by technology transfer and international funding, is helping to reduce production costs and improve global supply security-further fueling the sustained growth of the inactivated vaccines market.

SCOPE OF STUDY:

The report analyzes the Inactivated Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Viral Vaccine Type, Bacterial Vaccine Type); Inactivation Method (Solvent Detergent Method, Radiation Method, pH Concentration, Other Inactivation Methods); Administration Route (Oral, Subcutaneous, Intravenous); End-User (Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Astellas Pharma Inc.
• Bavarian Nordic A/S
• Bharat Biotech International Ltd.
• Biological E Limited
• Boehringer Ingelheim International GmbH
• CanSino Biologics Inc.
• CSL Limited
• Daiichi Sankyo Company, Limited
• Emergent BioSolutions Inc.
• GlaxoSmithKline plc
• Hualan Biological Engineering Inc.
• Inovio Pharmaceuticals, Inc.
• Johnson & Johnson Services Inc.
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Novavax, Inc.
• Pfizer Inc.
• Sanofi Pasteur
• Serum Institute of India Pvt. Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Inactivated Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Emphasis on Routine Immunization Programs Drives Demand for Inactivated Vaccines
  • Increased Preference for Well-Established Vaccine Technologies Supports Market Stability Amid Emerging Threats
  • Global Shift Away From Live Vaccines in Immunocompromised Populations Strengthens Case for Inactivated Platforms
  • Surge in Demand for Safe, Scalable Vaccine Production Platforms Accelerates Adoption of Inactivated Formulations
  • Regulatory Endorsement of Inactivated Vaccines for Pediatric and Elderly Populations Expands Application Scope
  • Growing Public Trust in Inactivated Vaccines Amid Vaccine Hesitancy Supports Uptake in Developed Markets
  • Expansion of Travel Medicine and Pre-Exposure Vaccination Drives Market for Inactivated Viral and Bacterial Vaccines
  • WHO and GAVI Support for Inactivated Vaccine Procurement in LMICs Fuels Global Immunization Equity
  • R&D Investments in Adjuvant Technologies Improve Immunogenicity and Dosing Efficiency of Inactivated Vaccines
  • Use of Inactivated Platforms in Combination and Multivalent Vaccines Enhances Pediatric Coverage and Compliance
  • Rising Demand for Thermostable Vaccine Formulations Boosts Development of Heat-Resistant Inactivated Products
  • Emergence of Pandemic and Outbreak Scenarios Repositions Inactivated Vaccines as Rapid-Response Tools
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Inactivated Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Inactivated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Viral Vaccine Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Viral Vaccine Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Viral Vaccine Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Bacterial Vaccine Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Bacterial Vaccine Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Bacterial Vaccine Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Specialty Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Specialty Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Homecare Settings End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Homecare Settings End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Homecare Settings End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Solvent Detergent Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Solvent Detergent Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Solvent Detergent Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Radiation Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Radiation Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Radiation Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for pH Concentration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for pH Concentration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for pH Concentration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Inactivation Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Inactivation Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Other Inactivation Methods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 44: USA Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• JAPAN
  • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• CHINA
  • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 80: China Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• EUROPE
  • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Inactivated Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• FRANCE
  • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 107: France Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: France 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• GERMANY
  • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Germany 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 143: UK Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Russia 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Inactivated Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Australia 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• INDIA
  • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 218: India Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: India 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: South Korea 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Inactivated Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Argentina 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Brazil 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Mexico 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Inactivated Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Iran 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Israel 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: UAE 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030
• AFRICA
  • Inactivated Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Inactivated Vaccines by Vaccine Type - Viral Vaccine Type and Bacterial Vaccine Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Inactivated Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Viral Vaccine Type and Bacterial Vaccine Type for the Years 2015, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Inactivated Vaccines by End-user - Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Inactivated Vaccines by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User and Other End-Users for the Years 2015, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Inactivated Vaccines by Inactivation Method - Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Inactivated Vaccines by Inactivation Method - Percentage Breakdown of Value Sales for Solvent Detergent Method, Radiation Method, pH Concentration and Other Inactivation Methods for the Years 2015, 2025 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Inactivated Vaccines by Administration Route - Oral, Subcutaneous and Intravenous Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Africa 15-Year Perspective for Inactivated Vaccines by Administration Route - Percentage Breakdown of Value Sales for Oral, Subcutaneous and Intravenous for the Years 2015, 2025 & 2030

IV. COMPETITION